Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat + Paclitaxel in Metastatic Breast Cancer
NCT01256762Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of imetelstat in breast cancer (2 arms), sponsored by Geron Corporation. Primary endpoint: Progression-Free Survival at 9 months. Started Nov 2010; status: completed.
02
Drugs
imetelstat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01256762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256762.